MedTrace Logo

New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence

NCT05410028 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2022-06-08

No results posted yet for this study

Summary

In this study, mass spectrometry was used to analyze immune inflammation-related protein complexes, post-translational modified glycopeptide omics and tumor-related metabolomics in serum, respectively, in order to find potential metabolic small molecule biomarkers or marker profiles that can be used for early diagnosis of cancer recurrence.

Conditions

Interventions

OTHER

No intervention in clinical treatment

No intervention in clinical treatment

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-03
Primary Completion
2024-03-03
Completion
2026-03-03

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05410028 on ClinicalTrials.gov